• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,368
2,297
1,863
1,846
1,724

COUNTRY

872
646
269
253
211

CATEGORIES

  • 858
  • 187
  • 678
  • 1,126
    • 99
  • 389
  • 270
  • 252
  • 65
  • 378
  • 688
  • 1,320
  • 1,354
  • 625
  • 884
  • 1,690
  • 2,672
    • 574
    • 118
    • 550
    • 75
    • 526
    • 43
    • 505
    • 18
    • 18
    • 23
  • 507
  • 730
  • 0
  • 93

PRICE

6,753
11,392
17,841
25,099

PUBLISHED

1,958
2,815
7,348
25,099

PRODUCT TYPE

20,978
2,901
870
164
74
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Tresiba (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes...

July 2013
FROM

Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type...

July 2013
FROM

LY2605541 (Type 2 Diabetes) - Forecast and Market Analysis to 2022

LY2605541 (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “LY2605541 (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2...

July 2013
FROM

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - China Drug Forecast and...

July 2013
FROM

Drug Addiction - Pipeline Review, H2 2013

Drug Addiction - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Drug Addiction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

July 2013
FROM

Respiratory Depression - Pipeline Review, H2 2013

Respiratory Depression - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Respiratory Depression - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2013

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2013', provides an overview of the indication’s...

July 2013
FROM

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2013

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H2 2013', provides an overview...

July 2013
FROM

Anaplastic Astrocytoma - Pipeline Review, H2 2013

Anaplastic Astrocytoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Anaplastic Astrocytoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Hypertrophic Scars - Pipeline Review, H2 2013

Hypertrophic Scars - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Hypertrophic Scars - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

July 2013
FROM

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2013

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

July 2013
FROM

Women Infertility - Pipeline Review, H2 2013

Women Infertility - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Women Infertility - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

July 2013
FROM

Helicobacter Pylori Infections - Pipeline Review, H2 2013

Helicobacter Pylori Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

July 2013
FROM

Essential Thrombocythemia - Pipeline Review, H2 2013

Essential Thrombocythemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Essential Thrombocythemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

July 2013
FROM

Brain Cancer - Pipeline Review, H2 2013

Brain Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

July 2013
FROM

Epithelial Ovarian Cancer - Pipeline Review, H2 2013

'Epithelial Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Epithelial Ovarian...

July 2013
FROM

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2013

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2013', provides an overview of the indication’s...

July 2013
FROM

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

July 2013
FROM

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Arimenda (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM
Loading Indicator

Our Clients

Our clients' logos